Compare BCAB & SRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCAB | SRBK |
|---|---|---|
| Founded | 2007 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 123.7M |
| IPO Year | 2020 | 2023 |
| Metric | BCAB | SRBK |
|---|---|---|
| Price | $0.13 | $16.98 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 26.9K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.16% |
| EPS Growth | 29.86 | ★ 138.36 |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $86.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $11.38 |
| 52 Week High | $1.43 | $18.04 |
| Indicator | BCAB | SRBK |
|---|---|---|
| Relative Strength Index (RSI) | 36.98 | 57.84 |
| Support Level | N/A | $16.27 |
| Resistance Level | $0.21 | $18.04 |
| Average True Range (ATR) | 0.02 | 0.40 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 15.65 | 92.31 |
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.